Your browser doesn't support javascript.
loading
Behçet disease: epidemiology, classification criteria and treatment modalities.
Fazaa, Alia; Makhlouf, Yasmine; Ben Massoud, Faiza; Miladi, Saoussen; Boussaa, Hiba; Ouenniche, Kmar; Souebni, Leila; Kassab, Selma; Chekili, Selma; Ben Abdelghani, Kawther; Laatar, Ahmed.
Afiliación
  • Fazaa A; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Makhlouf Y; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Ben Massoud F; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Miladi S; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Boussaa H; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Ouenniche K; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Souebni L; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Kassab S; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Chekili S; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Ben Abdelghani K; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
  • Laatar A; Department Rheumatolgy, Mongi Slim hospital, La marsa, Tunisia.
Expert Rev Clin Immunol ; : 1-12, 2024 Aug 11.
Article en En | MEDLINE | ID: mdl-39101633
ABSTRACT

INTRODUCTION:

Behçet disease (BD) is an inflammatory multisystem disorder of unknown etiology, believed to be triggered by infection and environmental factors in genetically predisposed individuals. The significance of understanding BD lies in its impact on global health due to its diverse clinical manifestations and geographical distribution. AREAS COVERED This review discusses the epidemiology of BD, emphasizing its prevalence estimated at 10.3 (95% CI, 6.1, 17.7) per 100,000 population, with higher rates observed in regions historically linked to the Silk Route. The criteria for diagnosis are explored, focusing on clinical manifestations that guide healthcare professionals in identifying and managing BD. Additionally, the review encompasses treatment strategies, highlighting TNF-alpha inhibitors as pivotal biologics and newer agents like IL-1 inhibitors and Ustekinumab that broaden the therapeutic options for BD. EXPERT OPINION Our work provides insights into the evolving landscape of treatments for BD, emphasizing the expanding role of newer agents alongside established therapies like TNF-alpha inhibitors.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Rev Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Túnez

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Expert Rev Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Túnez